Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Romosozumab Clear all
Recruiting Phase 3 Interventional

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Vitamin D, Calcium
Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 2 Interventional

Romosozumab/Denosumab Study for Premenopausal IOP

NCT04800367
View directory record Official record
Conditions
Premenopausal Idiopathic Osteoporosis
Interventions
Romosozumab Prefilled Syringe [Evenity], Denosumab 60 MG/ML Prefilled Syringe [Prolia]
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

NCT01081678
View directory record Official record
Conditions
Fracture Healing
Interventions
Placebo, Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Birmingham, Alabama • Pomona, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

NCT00907296
View directory record Official record
Conditions
Fracture Healing
Interventions
Romosozumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT01575834
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
7,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

NCT05775094
View directory record Official record
Conditions
Osteoporosis, Multiple Myeloma
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

NCT05101018
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injuries
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

NCT04545554
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

NCT02186171
View directory record Official record
Conditions
Osteoporosis in Men
Interventions
Romosozumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Bethesda, Maryland • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

NCT02016716
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Not applicable Interventional

Mechanisms of Anabolic Osteoporosis Therapy

NCT05688969
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
early versus late biopsy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Results available

Transition From Alendronate to Romosozumab (AMG 785)

NCT01588509
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Bisphosphonate
Drug
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Romosozumab in Women With Chronic SCI

NCT04708886
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Osteopenia, Osteoporosis, Spinal Cord Injuries, Chronic Spinal Paralysis
Interventions
Romosozumab, Alendronate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections

NCT07811999
View directory record Official record
Conditions
Healthy Participants
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Withdrawn Phase 2 Interventional

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

NCT07776613
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer (MBC)
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 4 Interventional

Romosozumab Use to Build Skeletal Integrity

NCT05058976
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions
Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Enrolling by invitation No phase listed Observational

Contribution of Bone to Urine Citrate

NCT06811363
View directory record Official record
Conditions
Osteoporosis
Interventions
Metabolic / prescribed diet, KCit Load (40 meq), Anti-resorptive agents, Anabolic Agents
Other · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

NCT01631214
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 18, 2026, 4:59 AM EDT